The BioProtect Balloon Spacer significantly preserves bowel, urinary, and sexual quality of life in prostate cancer patients undergoing radiation therapy over four years. The study showed ...
An expert discusses how proactive referral, multidisciplinary coordination, and early identification can optimize outcomes for patients with muscle-invasive bladder cancer, especially those with ...
TRAVERSE trial showed no increase in MACE with testosterone therapy, improving sexual function and depression symptoms without affecting diabetes or prostate cancer outcomes. T4DM trial found a 13% ...
LUGPA president Scott B. Sellinger, MD, FACS, highlights the key priorities and sessions at this year's LUGPA Annual Meeting. Stay current with the latest urology news and practice-changing insights — ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
DSUI's 2025 report emphasizes advancements in urology through visionary leadership, innovation, and transformative technologies, including AI-powered diagnostics and interdisciplinary research. Dr.
Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape. In this interview, conducted at the 2025 LUGPA Annual Meeting, Joshua J. Meeks, ...
This segment centers on the landmark EMBARK trial, which demonstrated a significant overall survival benefit with enzalutamide plus leuprolide. Freedland discusses the clinical implications of these ...
212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy. According to Hansen, 212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy (RLT) being developed for patients with ...
Data suggest that KIM-1 is prognostic for clinical outcomes in aRCC. A retrospective analysis of the COSMIC-313 trial (NCT03937219) suggests that KIM-1 is prognostic for clinical outcomes and may ...
Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. Host Amy Pearlman, MD, discusses premature ejaculation with Brian L. Steixner, MD, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback